Response to: Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations

Gelijkaardige items

• Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
  door: Masuda, Tomomi, et al.
  Gepubliceerd in: (2020)
• Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?
  door: Russano, Marco, et al.
  Gepubliceerd in: (2020)
• The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations
  door: Watanabe, Masahiro, et al.
  Gepubliceerd in: (2017)
• Cabozantinib and apixaban: an hitherto unreported interaction
  door: Santini, Daniele, et al.
  Gepubliceerd in: (2019)
• Afatinib Combined with Bevacizumab in the Treatment of Patients with Non-Small Cell Lung Cancer Harboring EGFR G719X, S768I or L861Q/P Mutations
  door: Han X, et al.
  Gepubliceerd in: (2024-11-01)